Immune-related adverse events are often a sign treatment is working. Dr Atkins discusses potential adverse events and how he counsels patients about them.
Case: A 62-Year-Old Female with Stage IV Melanoma
This is a video synopsis/summary of a Case-Based Peer Perspective, featuring Michael B. Atkins, MD.
A different perspective may be warranted regarding immune-related adverse events with immunotherapy. These toxicities, especially with nivolumab plus ipilimumab, are common but can be viewed as a marker of an active immune response rather than simply an adverse reaction. The goal of immunotherapy is to activate the immune system against the tumor, recognizing it as more foreign than normal tissues. Toxicity represents successful immune activation, which now needs modulation to prevent further attack on healthy tissue while maintaining antitumor activity.
Data show patients experiencing immune toxicities and stopping treatment do as well or better long-term compared with those without toxicity who continue therapy until progression. Thus, toxicity suggests the treatment is working on the immune system and hopefully on the tumor as well.
Video synopsis is AI-generated and reviewed by Targeted Oncology® editorial staff.
Dosing and Regimen Changes Promote Tolerability in Advanced Melanoma
March 14th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed dosing considerations and toxicity when choosing combination treatment for patients with melanoma. This is the second of 2 articles based on this event.
Read More
Dosing and Regimen Changes Promote Tolerability in Advanced Melanoma
March 14th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed dosing considerations and toxicity when choosing combination treatment for patients with melanoma. This is the second of 2 articles based on this event.
Read More
2 Commerce Drive
Cranbury, NJ 08512